Efficacy of an Algorithm-Guided Treatment Compared With Treatment as Usual: A Randomized, Controlled Study of Inpatients With Depression
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Medication algorithms have been proposed as effective means to offer optimal treatment and improved outcome for patients with severe mental illness. This single-center prospective study compared the efficacy and effects on treatment prescriptions of an algorithm-guided treatment regimen with treatment as usual (TAU) in depressed inpatients. METHODS: Depressed inpatient participants were randomized to an algorithm-guided standardized stepwise drug treatment regimen (SSTR, n = 74) or TAU (n = 74). The SSTR regimen included sleep deprivation, antidepressant monotherapy, lithium augmentation, monoamine oxidase inhibitor therapy, or electroconvulsive therapy guided by scores on the clinician-rated Bech-Rafaelsen Melancholia Scale. The primary outcome was time to remission (defined as a Bech-Rafaelsen Melancholia Scale score of < or =7). Secondary outcomes were remission rates, number of changes in treatment strategies (types), and the number of different prescribed medications over the treatment period. RESULTS: Patients receiving SSTR had a significantly shorter time to remission (7.0 +/- 0.9 weeks vs 12.3 +/- 1.8 weeks for TAU). Compared with that in remitters in SSTR, the number of strategy changes was significantly higher in TAU remitters (3.0 +/- 2.7 and 1.0 +/- 1.5) and had more psychotropic medications (fix agents: 3.0 +/- 1.5 and 1.9 +/- 1.1; optional agents: 1.5 +/- 1.0 and 0.9 +/- 0.7). Although more patients dropped out of the SSTR group (33 of SSTR, 12 of TAU), the probability of remission tended to be higher in SSTR. CONCLUSIONS: Algorithm-guided treatment produces better outcomes and less frequent medication changes than TAU. A systematic, stepwise, measurement-based approach to the treatment of depressed inpatients is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 3×
“In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, a measurement-based care approach including stepwise treatment procedures was assessed in a large outpatient sample with nonpsychotic MDD.25,26 Remission rates were 36.8% in step 1, 30.6% in step 2, 13.7% in step 3, and 13.0% in step 4.”
MethodInfluentialThe Functioning and Well-being of Depressed Patients: Results From the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.1989.03430070062031 · Cited by 2,130
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Berlim, M. T., & Turecki, G. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/070674370705200108 · Cited by 412 · cited 1×
“Only a minority of Btreatment-resistant[ patients have absolute resistance (ie, do not respond to an adequate dose and duration of treatment).(10) Rigorous treatment management may enhance outcomes.”
BackgroundCrossley, N. A., & Bauer, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0617 · Cited by 246
Self-citation
Cited by
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“A recent double-blind RCT of augmentation with low-dose aripiprazole (2 mg/day) did fi nd good tolerability but only marginal (and nonsignifi cant) effects (5.6% difference in response rate and 1.5 points difference in the MADRS) (Fava et al. 2012).”
BackgroundInfluentialSelf-citationPrognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis
van Diermen, L., van den Ameele, S., Kamperman, A. M., Sabbe, B. C. G., Vermeulen, T., Schrijvers, D., & Birkenhäger, T. K. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2017.28 · Cited by 334
Guo, T., Xiang, Y.-T., Xiao, L., Hu, C.-Q., Chiu, H. F. K., Ungvari, G. S., Correll, C. U., Lai, K. Y. C., Feng, L., Geng, Y., et al. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14050652 · Cited by 308
Ormel (2019) · doi:10.1097/yco.0000000000000505 · Cited by 102
Metadata
- Authors
- Bauer, M., Pfennig, A., Linden, M., Smolka, M. N., Neu, P., & Adli, M.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2009-08
- Volume
- 29
- Issue
- 4
- Pages
- 327-333
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2050323651
- Cited by
- 94
- References
- 7
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of an Algorithm-Guided Treatment Compared With Treatment as Usual: A Randomized, Controlled Study of Inpatients With Depression. https://app.cochat.ai/papers/10.1097/jcp.0b013e3181ac4839
- The paper
- Bauer, M., Pfennig, A., Linden, M., Smolka, M. N., Neu, P., & Adli, M. (2009). Efficacy of an Algorithm-Guided Treatment Compared With Treatment as Usual: A Randomized, Controlled Study of Inpatients With Depression. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3181ac4839
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.